Hims & Hers Health, Inc. Class A Common Stock (HIMS)
47.96
-2.02 (-4.04%)
NYSE · Last Trade: Aug 12th, 8:23 PM EDT
Detailed Quote
Previous Close
49.98
Open
48.73
Bid
48.17
Ask
48.20
Day's Range
47.25 - 48.98
52 Week Range
13.47 - 72.98
Volume
30,144,877
Market Cap
9.20B
PE Ratio (TTM)
60.71
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
36,697,931
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the disclosure of significant stock sales by top executives, including CEO Andrew Dudum. According to SEC filings, CEO Andrew Dudum sold 660,000 shares for a total of approximately $33.4 million. The selling was not limited to the CEO, as Chief Medical Officer Patrick Carroll also sold 60,000 shares valued at around $3.2 million, while the company's chief commercial officer also recently parted with shares. Such significant stock sales by a company's top leadership can raise concerns among investors about the firm's future prospects. These transactions come at a challenging time for the telehealth company, which has recently faced legal pressure from drugmaker Novo Nordisk and a class-action lawsuit related to its compounded weight-loss drug offerings.
NEW YORK - August 12, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. (NYSE: HIMS) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases.
RADNOR, PA - August 12, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
NEW YORK - August 11, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. (NYSE: HIMS) of a class action securities lawsuit.
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales
NEW YORK - August 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. (NYSE: HIMS) of a class action securities lawsuit.
Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks involved in this insightful analysis.
RADNOR, PA - August 7, 2025 ( NEWMEDIAWIRE ) - Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
